scholarly journals Quality of life across domains among individuals with treatment-resistant depression

2019 ◽  
Vol 243 ◽  
pp. 401-407 ◽  
Author(s):  
Heidemarie Lex ◽  
Yarden Ginsburg ◽  
Adam F. Sitzmann ◽  
Clara Grayhack ◽  
Daniel F. Maixner ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Resistant Depression

Magnetic seizure therapy in treatment-resistant depression: clinical, neuropsychological and metabolic effects

2014 ◽  
Vol 45 (5) ◽  
pp. 1073-1092 ◽  
Author(s):  
S. Kayser ◽  
B. H. Bewernick ◽  
A. Matusch ◽  
R. Hurlemann ◽  
M. Soehle ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Depressive Symptoms ◽  
Fdg Pet ◽  
Metabolic Effects ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Magnetic Seizure Therapy ◽  
Resistant Depression ◽  
Pet Scans

Background.Magnetic seizure therapy (MST), despite being in an early phase of clinical research, has been demonstrated to be associated with antidepressant efficacy. However, safety, tolerability and efficacy data in connection with functional brain activity from larger samples are lacking. The aim of this study was to determine clinical and cognitive effects of MST and the influence of MST on regional brain glucose metabolism.Method.Twenty-six patients suffering from treatment-resistant depression (TRD) underwent MST. Ten patients underwent a randomized trial and 16 patients an open-label study design. The primary outcome criterion was the severity of depressive symptoms assessed with the Hamilton Depression Rating Scale (HAMD). Depressive symptoms, tolerability and cognitive safety, along with social functioning and quality of life parameters, were assessed using various rating scales. A clinical follow-up visit 6 months following the completion of a course of MST and [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) scans of 12 patients were analysed.Results.A significant response to MST was demonstrated by 69% of the patient sample, with 46% meeting remission criteria. Anxiety ratings were significantly reduced in responders and their quality of life was improved. Half of the responders relapsed within 6 months. No cognitive side-effects were observed. FDG-PET scans showed a metabolic increase in the frontal cortex bilaterally and a decrease in the left striatum.Conclusions.Robust antidepressant and anti-anxiety efficacy of MST was demonstrated, and found to be associated with localized metabolic changes in brain areas that are strongly implicated in depression. Thus, MST presents an effective, well-tolerated and safe treatment option for patients unable to respond to other forms of therapy for depression.

scholarly journals 119 Assessment of Health-Related Quality of Life and Health Status in Patients with Treatment-resistant Depression

CNS Spectrums ◽  
2020 ◽  
Vol 25 (2) ◽  
pp. 277-278
Author(s):  
Carol Jamieson ◽  
Vanina Popova ◽  
Ella Daly ◽  
Kimberly Cooper ◽  
Madhukar H. Trivedi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Health Status ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Related Quality ◽  
Health Related ◽  
Resistant Depression ◽  
Anxiety Depression ◽  
Eq Vas

Abstract:Objective:To assess health-related quality of life (HRQoL) and health status of patients with treatment resistant depression (TRD), treated with esketamine nasal spray+oral antidepressant (ESK+AD) vs oral antidepressant+placebo nasal spray (AD+PBO) using European Quality of Life Group-5-Dimension-5-Level (EQ-5D-5L). The EQ-5D-5L descriptive system consists of five domains relevant for patients with depression (mobility, self-care, usual activities, pain, anxiety/depression) and the EQ-Visual Analogue Scale (EQ-VAS).Methods:Data from TRANSFORM-2 (NCT02418585), a randomized, double-blind short-term study were analyzed. Patients (18-64 years inclusive) with TRD were included. Patient reported health status change using EQ-5D-5L and EQ-VAS was measured from baseline to end of 4-week induction phase (endpoint). Each domain of EQ-5D-5L included 5 levels of perceived problems (L1: no problems; L5: extreme problems).Results:Full analysis set included 223 patients (ESK+AD: 114; AD+PBO: 109). At endpoint, mean (SD) change in health status index was 0.288 (0.2317) for ESK+AD group and 0.231 (0.2506) for AD+PBO group with higher score reflecting higher levels of functioning. At endpoint, percentage of patients reporting problems (grouped L2-L5 responses for each dimension) in ESK+AD vs AD+PBO group: mobility (13.5% vs 25.7%), self-care (16.2% vs 30.5%), usual activities (55.0% vs 71.4%), pain (38.7% vs 52.4%), and anxiety/depression (71.2% vs 78.1%). Mean (SD) change in EQ-VAS score at endpoint was 29.1 (26.32) for ESK+AD and 20.9 (26.60) for AD+PBO group.Conclusion:Greater improvement in HRQoL and health status using EQ-5D-5L and EQ-VAS was observed among patients with TRD treated with ESK+AD vs AD+PBO.Funding Acknowledgements:This study was sponsored by Janssen Research and Development, LLC.

scholarly journals PMH52 IMPROVEMENT IN QUALITY-OF-LIFE WITH RISPERIDONE AUGMENTATION IN TREATMENT-RESISTANT DEPRESSION

2004 ◽  
Vol 7 (3) ◽  
pp. 279
Author(s):  
D Walling ◽  
M Rupnow ◽  
C Canuso ◽  
G Gharabawi ◽  
I Turkoz ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Resistant Depression

The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature

2019 ◽  
Vol 242 ◽  
pp. 195-210 ◽  
Author(s):  
Karissa M. Johnston ◽  
Lauren C. Powell ◽  
Ian M. Anderson ◽  
Shelagh Szabo ◽  
Stephanie Cline
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Burden Of Treatment ◽  
Resistant Depression

Evaluation of the effects of rTMS on self-reported quality of life and disability in treatment-resistant depression: A THREE-D study

2020 ◽  
Vol 268 ◽  
pp. 127-133
Author(s):  
Peter Giacobbe ◽  
Karim Mithani ◽  
Ying Meng ◽  
Fidel Vila-Rodriguez ◽  
Zafiris J. Daskalakis ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Resistant Depression

A 6-Year Follow-up Study of Vagus Nerve Stimulation Effect on Quality of Life in Treatment-Resistant Depression

2018 ◽  
Vol 34 (4) ◽  
pp. e58-e60 ◽  
Author(s):  
François Trottier-Duclos ◽  
Véronique Desbeaumes Jodoin ◽  
Marie-Pierre Fournier-Gosselin ◽  
François Richer ◽  
Nathalie Desjardins ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Vagus Nerve ◽  
Nerve Stimulation ◽  
Vagus Nerve Stimulation ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Follow Up Study ◽  
Resistant Depression

scholarly journals Clinical Features and Outcomes of 124 Italian Patients With Treatment Resistant Depression: A Real-World, Prospective Study

2021 ◽  
Vol 12 ◽  
Author(s):  
Giulio Perugi ◽  
Paola Calò ◽  
Sergio De Filippis ◽  
Gianluca Rosso ◽  
Antonio Vita ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Real World ◽  
Depressive Episode ◽  
Major Depressive Episode ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Major Depressive ◽  
The Mean ◽  
Resistant Depression

Introduction: Treatment-resistant depression (TRD) is a debilitating condition affecting 20–30% of patients with major depressive disorders (MDD). Currently, there is no established standard of care for TRD, and wide variation in the clinical approach for disease management has been documented. Real-world data could help describe TRD clinical features, disease burden, and treatment outcome and identify a potential unmet medical need.Methods: We analyzed the Italian data from a European, prospective, multicentric, observational cohort study of patients fulfilling TRD criteria by the European Medicine Agency, with moderate to severe major depressive episode, and starting a new antidepressant treatment according to routinary clinical practice. They were followed up for minimum 6 months. Treatments received throughout the study period, disease severity, health-related quality of life and functioning were prospectively recorded and analyzed.Results: The Italian subcohort included 124 TRD patients (30.2% of patients of the European cohort; mean age 53.2 [sd = 9.8], women: 82, 66.1%). At enrollement, the mean (SD) duration of MDD was 16 years (sd = 11.1) and the mean duration of the ongoing major depressive episode (MDE) was 97.5 weeks (sd = 143.5); low scores of quality of life and functioning were reported. The most frequently antidepressant classes started at baseline (data available for 98 subjects) were selective serotonin reuptake inhibitors (SSRI, 42 patients [42.9%]) and serotonin-norepinephrine reuptake inhibitors (SNRI, 32 patients [32.7%]). In terms of treatment strategies, 50 patients (51%) started augmentation therapies, 18 (18.4%) combination therapies and 24 (24.5%) monoterapies (6 patients [6%] started a non-antidepressant drug only). Fourteen patients (11.3%) were treated with a psychosocial approach, including psychotherapy. After 6 months of treatment, clinical assessments were collected for 89 patients: 64 (71.9%) showed no response, 9 (10.1%) response without remission and 16 (18.0%) were in remission; non-responder patients showed lower quality of life and higher disability scores than responder patients.Conclusions: In our sample of TRD patients, we documented substantial illness burden, low perceived quality of life and poor outcome, suggesting an unmet treatment need in TRD care in Italy.Registration Number:ClinicalTrials.gov, number: NCT03373253.

Sign in / Sign up

Export Citation Format

Share Document